Page 99 - The Flying Publisher Guide to Hepatitis C Treatment

References | 99

Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous
clearance of hepatitis C virus. Nature 2009;461:798-801.
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism
improves viral kinetics and is the strongest pretreatment predictor of
sustained virologic response in genotype 1 hepatitis C virus.
Gastroenterology 2010;139:120-9.
Thomson BJ, Kwong G, Ratib S, et al. Response rates to combination therapy for
chronic HCV infection in a clinical setting and derivation of probability
tables for individual patient management. J Viral Hepat 2008;15:271-8.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus
ribavirin for chronic HCV infection in HIV-infected patients. N Engl J Med
2004;351:438-50.
Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for
hepatitis C virus infection. World J Gastroenterol 2011;17:419-32.
Vermehren J, Kau A, Gärtner BC, Göbel R, Zeuzem S, Sarrazin C. Differences
between two real-time PCR-based hepatitis C virus (HCV) assays(RealTime
HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification
assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin
Microbiol 2008;46:3880-91.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict
both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
Hepatology 2003;38:518-26.
Walter T, Scoazec JY, Guillaud O, et al. Long-Term Antiviral Therapy for
Recurrent Hepatitis C After Liver Transplantation in Nonresponders:
Biochemical, Virological and Histological Impact. Liver Transpl 2009;15:54-
63.
Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A
suppresses replication of hepatitis C virus genome in cultured hepatocytes.
Hepatology 2003;38:1282-8.
Watt K, Veldt B, Charlton M. A practical guide to the management of HCV
infection following liver transplantation. Am J Transplant 2009;9:1707-13.
Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver
Transplantation Society expert panel consensus conference on liver
transplantation and hepatitis C. Liver Transpl 2003;9:S1–9.
Wilkinson M, Crawford V, Tippet A, et al. Community based treatment for
chronic hepatitis C in drug users: high rates of compliance with therapy
despite on-going drug use. Aliment Pharmacol Ther 2009;29:29-37.
Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase
in chronic hepatitis: relationship to cirrhosis: Gastroenterology
1988;95:734-9.
Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response
rates in children with chronic hepatitis C receiving peginterferon alfa-2b
plus ribavirin. J Hepatol 2010;52:501-7.
Zeuzem S, Arora S, Bacon B, et al. Pegylated interferon-lambda (pegIFN-[lambda])
shows superior viral response with improved safety and tolerability versus
pegIFN-[alpha]-2a in HCV patients (G1/2/3/4): EMERGE phase IIb through
week 12. J Hepatol 2011;54:S538-9.